Therefore, Abemaciclib was approved to be used with endocrine therapy for adjunctive therapy in early breast cancer with HR+/HER2, lymph node-positive, and high risk of recurrence with KI-67 20%. This evidence concerns the gene ERBB2 and breast cancer.